Actelion Ltd (ATLN.VX)

ATLN.VX on Virt-X Level 1

109.20CHF
8:27am EDT
Price Change (% chg)

CHF-0.10 (-0.09%)
Prev Close
CHF109.30
Open
CHF109.50
Day's High
CHF110.30
Day's Low
CHF108.80
Volume
191,037
Avg. Vol
589,860
52-wk High
CHF115.50
52-wk Low
CHF59.80

ATLN.VX

Chart for ATLN.VX

About

Actelion Ltd is a Swiss biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled formulation of... (more)

Overall

Beta: 0.74
Market Cap (Mil.): CHF12,474.24
Shares Outstanding (Mil.): 114.13
Dividend: 1.20
Yield (%): 1.10

Financials

  ATLN.VX Industry Sector
P/E (TTM): 18.80 103.84 36.09
EPS (TTM): 5.81 -- --
ROI: 34.70 -0.24 18.19
ROE: 41.35 -1.24 19.06
Search Stocks

European shares bounce back, helped by earnings reports

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

European shares bounce back as Ukraine tension ease

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

European shares up as Ukraine rebels allow improved access

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

REFILE-UPDATE 2-Actelion CEO seeks to defuse takeover talk

ZURICH, July 22 - Actelion Chief Executive Jean-Paul Clozel said he was determined to keep the Swiss biotech company independent, batting away speculation it could become the next takeover target for U.S. firms seeking lower taxes by relocating abroad.

22 Jul 2014

Actelion CEO seeks to diffuse takeover talk

ZURICH - Actelion Chief Executive Jean-Paul Clozel said he was determined to keep the Swiss biotech company independent, batting away speculation it could become the next takeover target for U.S. firms seeking lower taxes by relocating abroad.

22 Jul 2014

European shares rebound as Ukraine rebels hand over black boxes

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

BRIEF-Actelion rises 4.3 pct after hikes profit forecast

July 22 - Actelion Ltd : * Shares in Actelion rise 4.3 percent after hikes profit forecast

22 Jul 2014

BRIEF-Actelion indicated 3.2 pct higher - premarket

July 22 - Actelion Ltd : * Shares indicated 3.2 percent higher in premarket trade

22 Jul 2014

Actelion hikes full-year profit forecast

ZURICH, July 22 - Actelion hiked its 2014 profit forecast for the second time this year on Tuesday, encouraged by strong sales of its new heart and lung drug Opsumit.

22 Jul 2014

Deals of the day- Mergers and acquisitions

(Adds Oracle, Valeant, SoftBank Corp, Wintershall, Santander Totta, Ilva, GE, Alstom, Ryanair, First Quantum, Actelion, Pop Vicenza)

17 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks